13 results about "Myosin" patented technology

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The present invention relates to novel blood-brain barrier (BBB) ​​permeable substituted bicyclic derivatives capable of selectively inhibiting myosin light chain phosphate phosphorylation mediated by ROCK2 and / or Rho kinase, compositions comprising such derivatives, methods for preparing such derivatives and / or compositions, and methods for using such derivatives and / or compositions.

This invention pertains to the pharmaceutical field and relates to a class of substituted indene compounds and their uses. Specifically, this invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I). The compounds and pharmaceutical compositions thereof involved in this invention, as myosin inhibitors, can be used to prepare medicaments for the prevention or treatment of myosin-related diseases, and particularly for the treatment of hypertrophic cardiomyopathy.

The application discloses a benzisothiazole carboxamide compound and application thereof. The benzisothiazole carboxamide compound has the characteristics of high specificity and high activity as an inhibitor of myosin motor domain, and can significantly inhibit the growth and development process and pathogenicity of pathogenic fungi, especially Pyricularia oryzae.

1. The name of the design product: packaging box (recombinant mussel myosin repair dressing). 2. The use of the design product: for the packaging of medicines. 3. The design points of the design product: the combination of patterns and colors. 4. The picture or photo that best shows the design points: perspective view. 5. The design for which protection is sought contains colors.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.

The present invention provides in vitro methods of for the production of milk-like products in a bioreactor. The method comprising providing a bioreactor comprising a culture vessel and a membrane insert that divides the culture vessel into an apical compartment and a basal compartment. A confluent layer of mammary-derived cells, optionally mammosphere-derived cells, is adhered to the apical facing surface of the membrane. Lactation media is provided to the basal compartment, optionally the lactation media comprises TGFb inhibitor, an inhibitor of intracellular actomyosin contractility such as a ROCK inhibitor or a myosin II inhibitor, and / or prolactin. Milk-like product is isolated from the apical compartment. Optionally a priming treatment is added to growth media of the hyperconfluent cell monolayer before switching to lactation.

This invention pertains to the pharmaceutical field and relates to a class of substituted indene compounds and their uses. Specifically, this invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I). The compounds and pharmaceutical compositions thereof involved in this invention, as myosin inhibitors, can be used to prepare medicaments for the prevention or treatment of myosin-related diseases, and particularly for the treatment of hypertrophic cardiomyopathy.

Human skeletal muscle stem cells were generated from facioscapulohumeral muscular dystrophy (FSHD) and healthy control iPSC using a transgene-free skeletal muscle differentiation protocol and production of stable iMyoblasts. Analyses revealed that FSHD and healthy control iMyoblasts are embryonic-like myogenic cells that undergo myotube differentiation ex vivo by growth factor depletion and are efficiently transplantable into the tibialis anterior (TA) muscles of NSG mice, where human muscle under-goes embryonic-to-adult myosin isoform switching. The DUX4 FSHD disease gene maintains its hypomethylated disease state inFSHD iPSC and iMyoblast, and its expression is upregulated during myotube differentiation and in muscle xenografts. Consequently, these iMyoblasts accurately exhibit the molecular pathology of human muscular dystrophies and are useful for the development of drug, gene editing and stem cell therapeutics.